Stockscreener 앱 받기
513.12
1.51%
-7.88
전일 마감가:
$521.00
열려 있는:
$523.23
하루 거래량:
415.57K
Relative Volume:
0.86
시가총액:
$22.01B
수익:
$3.17B
순이익/손실:
$1.29B
주가수익비율:
18.94
EPS:
27.0947
순현금흐름:
$1.01B
1주 성능:
+2.68%
1개월 성능:
-4.24%
6개월 성능:
+8.39%
1년 성능:
+65.17%
1일 변동 폭
$512.29
$528.02
1주일 범위
$499.96
$535.77
52주 변동 폭
$302.19
$609.35
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
513.12 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
18.18 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.00 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
37.34 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.73 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
United Therapeutics (NASDAQ: UTHR) CEO sale part of 1,734,410-option 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) legal chief sells 8,300 shares - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO trades under 1,734,410-option 10b5-1 plan - Stock Titan
United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns - ChartMill
ETFs Investing in United Therapeutics Corporation Stocks - TradingView
United Therapeutics (UTHR) CEO sells shares under preset trading plan - Stock Titan
United Therapeutics Corp (UTHR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares - Stock Titan
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript - AOL.com
United Therapeutics Completes Enrollment in Phase 3 PPF Trial of Tyvaso - marketscreener.com
United Therapeutics completes enrollment in lung fibrosis trial - Investing.com
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis - marketscreener.com
United Therapeutics Corporation Completes Enrollment Of TETON-PPF Study Of Inhaled Treprostinil For Progressive Pulmonary Fibrosis - marketscreener.com
United Therapeutics Corporation (UTHR) Stock Analysis: Potential 30% Upside Captivates Investors - DirectorsTalk Interviews
Mid Cap Index Fund's United Therapeutics Corp(UTHR) Holding History - GuruFocus
United Therapeutics CEO Martine Rothblatt sells $4.79m in stock By Investing.com - Investing.com South Africa
United Therapeutics CEO Martine Rothblatt sells $4.79m in stock - Investing.com
United Therapeutics (UTHR) CEO Rothblatt exercises 9,500 options and sells 9,500 shares via 10b5-1 plan - Stock Titan
UTHR|United Therapeutics Corp|Price:499.730|Chg%:-1.540 - TradingKey
United Therapeutics CEO Rothblatt sells $4.89m in stock By Investing.com - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $4.89m in stock - Investing.com
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics Corp (UTHR) CEO’s trust sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) Stock Looks Undervalued Despite Fresh NDA Filings - simplywall.st
United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play - ChartMill
United Therapeutics Corp (UTHR) CEO trades 9,500 shares after option exercise - Stock Titan
UNITED THERAPEUTICS CORP (UTHR.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
United Therapeutics chairperson & CEO sells $5.05m in stock By Investing.com - Investing.com Australia
United Therapeutics (UTHR) CEO trades 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics chairperson & CEO sells $5.05m in stock - Investing.com
Baylor College of Medicine strikes multimillion-dollar deal with United Therapeutics for transplant center - The Business Journals
United Therapeutics (UTHR) CEO trades 9,500 shares under 10b5-1 option plan - Stock Titan
Assenagon Asset Management S.A. Purchases 37,355 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise - Stock Titan
United Therapeutics (NASDAQ:UTHR) Sees Strong Trading VolumeShould You Buy? - MarketBeat
United Therapeutics EVP & general counsel Mahon sells $4.29m in shares - Investing.com South Africa
United Therapeutics Corporation $UTHR Shares Sold by Bank of America Corp DE - MarketBeat
United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock - MarketBeat
United Therapeutics Balances Tyvaso Woes With Pipeline Wins - The Globe and Mail
United Therapeutics (UTHR) counsel exercises options, sells 8,300 shares - Stock Titan
United Therapeutics Corp (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
Royal Bank Of Canada Has Lowered Expectations for United Therapeutics (NASDAQ:UTHR) Stock Price - marketbeat.com
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark - Yahoo Finance
United Therapeutics Corp (UTHR) (Q2 2026) Earnings Call Highligh - GuruFocus
United Therapeutics Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
BofA cuts United Therapeutics stock price target on Tyvaso sales - Investing.com
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.24%
자본화:
|
볼륨(24시간):